MYSTERIOUS: Eha - You Need To See This

Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out

Incyte (NASDAQ:INCY) Chief Medical Officer Steven Stein outlined the company’s development priorities across hematology, oncology and immunology, with a particular focus on its mutant CALR antibody 989, during a company news event. Stein said myeloproliferative neoplasms remain “front and center” f

MarketBeat · May 25

The Road To Immortality – Inside the Elite World of Life Extension

From high-tech biohacking to holistic wellness: in the race to live forever, who’s benefitting from the science of longevity – and what does health optimisation really look like?

Marie Claire · Jan 30

Biden Administration Strips Federal Funding From Nonprofit at Center of COVID Lab Leak Controversy

Federal officials say EcoHealth Alliance failed to properly report on its gain-of-function research at the Wuhan Institute of Virology and to monitor safety conditions there.

Reason · May 15, 2024